Leicester Royal Infirmary Expands Aseptic Pharmacy to Triple Cancer Treatment Production Capacity
Key Insights
Leicester City Council has approved University Hospitals of Leicester NHS Trust's planning application to extend the Osborne building for a new aseptic pharmacy facility.
The expansion will increase sterile isolator capacity from two to five units, enabling faster preparation of chemotherapy (search) and other injectable cancer (search) medicines.
The new facility is designed to support clinical research by enabling safe preparation of trial medications and expanding participation in clinical trials.
University Hospitals of Leicester NHS Trust has received planning approval to significantly expand its cancer (search) treatment production capabilities through a new aseptic pharmacy facility at Leicester Royal Infirmary (search). Leicester City Council approved the planning application to extend the Osborne building, marking a substantial investment in oncology infrastructure that will enhance both patient care and clinical research capacity.
Tripling Production Capacity Through Advanced Sterile Technology
The expansion will increase the number of isolators from two to five units. These containment devices provide the required sterilized environment for preparing injectable medicines, particularly chemotherapy (search) treatments. According to the NHS, aseptic pharmacy services provide sterile controlled environments essential for the safe preparation of injectable medicines.
Jon Melbourne, chief operating officer at UHL, emphasized the clinical significance of the expansion: "By increasing our capacity to prepare medicines such as chemotherapy (search), we will be able to treat more patients, more quickly."
Supporting Clinical Research and Trial Participation
The facility has been strategically designed to advance clinical research capabilities. Melbourne noted that the new aseptic pharmacy will enable "the safe preparation of trial medications, with additional isolators providing the flexibility to respond to rising patient demand and expand participation in clinical trials."
This dual-purpose approach addresses both immediate patient care needs and the growing demand for clinical trial participation, positioning the facility as a hub for both treatment delivery and research advancement.
Timeline and Strategic Impact
The new center is scheduled to open in April next year, according to Melbourne. He described the facility as representing "a major step forward" in how the trust delivers cancer (search) care.
The expansion reflects the increasing demand for specialized cancer (search) treatments and the need for enhanced production capacity to support both standard care protocols and investigational therapies. The additional isolators will provide operational flexibility to accommodate fluctuating patient volumes and expanding research programs.